NASDAQ
22.04.26 | 17:50
7,750 US-Dollar
+2,92 % +0,220
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Leerink reiterates Fulcrum Therapeutics stock rating on FDA flexibility | 1 | Investing.com | ||
| 19.03. | Fulcrum Therapeutics, Inc.: MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle ... | 1 | GlobeNewswire (USA) | ||
| 10.03. | Fulcrum Therapeutics: Strategischer Fokus auf Sichelzell-Medikament nach positiven Studiendaten | 2 | Investing.com Deutsch | ||
| 09.03. | Stifel: Ipsen-Rückzug könnte Aktie von Fulcrum Therapeutics belasten | 2 | Investing.com Deutsch | ||
| 09.03. | Fulcrum Therapeutics stock may face pressure on Ipsen withdrawal, Stifel says | 2 | Investing.com | ||
| 06.03. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 24.02. | Fulcrum Therapeutics stock falls as sickle cell trial misses target | 2 | Investing.com | ||
| FULCRUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.02. | Leerink bestätigt "Outperform"-Rating für Fulcrum Therapeutics nach Daten zur Sichelzellkrankheit | 4 | Investing.com Deutsch | ||
| 24.02. | Leerink reiterates Fulcrum Therapeutics stock rating on SCD data | 1 | Investing.com | ||
| 24.02. | Fulcrum Therapeutics: BofA bestätigt Underperform-Rating und Kursziel von 7 $ | 2 | Investing.com Deutsch | ||
| 24.02. | BofA reiterates Fulcrum Therapeutics stock Underperform rating at $7 | 2 | Investing.com | ||
| 24.02. | Stifel reiterates Fulcrum Therapeutics stock rating on drug data | 1 | Investing.com | ||
| 24.02. | Fulcrum Therapeutics shares fall on profit-taking, Oppenheimer says | 1 | Investing.com | ||
| 24.02. | What's Going On With Fulcrum Therapeutics Stock Tuesday? | 2 | Benzinga.com | ||
| 24.02. | Fulcrum Therapeutics GAAP EPS of -$0.31 in-line | 4 | Seeking Alpha | ||
| 24.02. | Fulcrum Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 24.02. | Fulcrum Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 24.02. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 | 650 | GlobeNewswire (Europe) | - Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) - 20 mg cohort demonstrated rapid and robust fetal hemoglobin... ► Artikel lesen | |
| 24.02. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease | 285 | GlobeNewswire (Europe) | ? Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular... ► Artikel lesen | |
| 24.02. | Fulcrum Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,685 | +0,62 % | EQS-News: Evotec SE: Evotec ernennt Dr. Ingrid Müller zur Chief Operating Officer | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Dr. Ingrid Müller zur Chief Operating Officer
15.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| QIAGEN | 34,075 | -1,80 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| MODERNA | 46,640 | +0,88 % | Moderna - MRNA: Impfstoff-Aktie mit mega-starkem Comeback! | + 100 Prozent in 6 Monaten! mrRNA-Impfstoffe gegen Krebs, Grippe & RSV bei Moderna in der Pipeline! Neue Rallye trotz US-Gesundheitsminister Robert F. Kennedy? Moderna (MRNA) - ISIN US60770K1079 Rückblick:... ► Artikel lesen | |
| VALNEVA | 2,405 | -7,92 % | EILMELDUNG bei Valneva: Der Kurs nähert sich einer gefährlichen Marke - So reagieren erfahrene Anleger jetzt | ||
| AMGEN | 294,60 | +0,19 % | Congressional Trading Report: Rep. Maria Elvira Salazar Bought Over $221K In Amgen Stock | ||
| NOVAVAX | 7,220 | -0,28 % | H.C. Wainwright reiterates Novavax stock rating on vaccine study | ||
| STRYKER | 283,50 | +1,54 % | Following Stryker Cyberattack, Avatier Launches Identity Challenge Card to Protect Organizations When Standard Security Fails | New Solution Delivers the First Auto-Enrolled, Air-Gapped Multi-Factor Authentication (MFA) That Can Be Deployed Enterprise-Wide in a Single Day: No Devices, Apps, or Network Connectivity RequiredPLEASANTON... ► Artikel lesen | |
| BIOGEN | 163,00 | +2,79 % | Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen | |
| ILLUMINA | 111,28 | -1,12 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,835 | +0,98 % | CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? | ||
| REGENERON PHARMACEUTICALS | 638,00 | +0,08 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 17.04.2026 -2- | The following instruments on XETRA do have their last trading day on 17.04.2026.Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026.ISIN Name US5719032022 Marriott International... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,230 | +3,32 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results | Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,150 | +1,04 % | Better Long-Term Buy: Eli Lilly or Viking Therapeutics? | ||
| EDITAS MEDICINE | 2,800 | -0,71 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,400 | -1,72 % | NurExone Aufbruch in den US-Markt für Exosomen |
Das Unternehmen FULCRUM THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 7,750 Euro und damit +2,92 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FULCRUM THERAPEUTICS INC finden Sie auf Wallstreet Online.